Clinical trials of left atrial appendage closure systems for stroke prevention should aim to show that a patient can come off oral anticoagulation therapy within 45 days of treatment, while demonstrating a solid safety profile out to two years, according to FDA.
There are yet no LAA closure devices approved for preventing stroke in atrial fibrillation patients in the U.S. Boston Scientific’s...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?